R B Arlinghaus
About
In The Last Decade
R B Arlinghaus
17 papers receiving 691 citations
Peers
Comparison fields: 5 of 51
- Hematology 469
- Genetics 370
- Molecular Biology 204
- Rheumatology 185
- Oncology 169
Countries citing papers authored by R B Arlinghaus
This map shows the geographic impact of R B Arlinghaus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R B Arlinghaus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R B Arlinghaus more than expected).
Fields of papers citing papers by R B Arlinghaus
This network shows the impact of papers produced by R B Arlinghaus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R B Arlinghaus. The network helps show where R B Arlinghaus may publish in the future.
Co-authorship network of co-authors of R B Arlinghaus
This figure shows the co-authorship network connecting the top 25 collaborators of R B Arlinghaus. A scholar is included among the top collaborators of R B Arlinghaus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R B Arlinghaus. R B Arlinghaus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 19 | |
| 2 | Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). | 148 |
| 3 | Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein. | 20 |
| 4 | 162 | |
| 5 | 10 | |
| 6 | 34 | |
| 7 | 1 | |
| 8 | 14 | |
| 9 | 1 | |
| 10 | Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients. | 39 |
| 11 | 8 | |
| 12 | Differential effects of tumor promoters on P210bcr-abl expression. | 4 |
| 13 | A novel 53 kDa protein complexed with P210bcr-abl in human chronic myelogenous leukemia cells. | 8 |
| 14 | 37 | |
| 15 | 53 | |
| 16 | 8 | |
| 17 | 159 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.